Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP, Human Resources | February 05, 2013 | February 07, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date February 05, 2013 · Filed February 07, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,382 |
Reported balance
After 2013-02-05 transaction · row 1
1 source rowRow 1 · 2013-02-05 · Grant · Acquired 10,166 · Balance 25,382 F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.11 · Expires 2023-02-04 | Direct | 45,750 |
Reported balance
After 2013-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2013-02-05 · Grant · Acquired 45,750 · Balance 45,750 F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 1,965 |
Reported balance
Holding disclosure · report date 2013-02-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,965 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products.
F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2011 Filed Apr 27, 2011 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 14,297 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-11-024585 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,907 Underlying: Common Stock · 14,297 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/12/2007. Read SEC document |
| April 26, 2011 Filed Apr 27, 2011 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14,297 | $50.50 | $721,998.50 |
DisclosureSEC source: 0001209191-11-024585 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 26, 2011 Filed Apr 27, 2011 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 14,297 | $28.84 | $412,325.48 |
DisclosureSEC source: 0001209191-11-024585 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2011 Filed Apr 26, 2011 19:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 953 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-11-024395 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,204 Underlying: Common Stock · 953 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 7/12/2007. Read SEC document |
| April 25, 2011 Filed Apr 26, 2011 19:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 953 | $50.00 | $47,650.00 |
DisclosureSEC source: 0001209191-11-024395 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 25, 2011 Filed Apr 26, 2011 19:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 953 | $28.84 | $27,484.52 |
DisclosureSEC source: 0001209191-11-024395 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 13,343 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-11-015489 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,157 Underlying: Common Stock · 13,343 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/12/2007. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 13,343 | $50.00 | $667,150.00 |
DisclosureSEC source: 0001209191-11-015489 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 13,343 | $28.84 | $384,812.12 |
DisclosureSEC source: 0001209191-11-015489 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2011 Filed Mar 3, 2011 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 11,438 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-11-014962 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,625 Underlying: Common Stock · 11,438 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| March 02, 2011 Filed Mar 3, 2011 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,438 | $47.50 | $543,305.00 |
DisclosureSEC source: 0001209191-11-014962 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 02, 2011 Filed Mar 3, 2011 20:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,438 | $18.93 | $216,521.34 |
DisclosureSEC source: 0001209191-11-014962 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 11,437 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-11-000020 · edgar.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,063 Underlying: Common Stock · 11,437 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,437 | $45.00 | $514,665.00 |
DisclosureSEC source: 0000875320-11-000020 · edgar.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,437 | $18.93 | $216,502.41 |
DisclosureSEC source: 0000875320-11-000020 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 45,750 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000013 · edgar.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-11-000013 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| January 25, 2011 Filed Jan 26, 2011 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 471 | $40.78 | $19,207.38 |
DisclosureSEC source: 0000875320-11-000006 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,076 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan established under Rule 10b5-1. Read SEC document |
| January 21, 2011 Filed Jan 25, 2011 18:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,709 | $39.93 | $68,240.37 |
DisclosureSEC source: 0000875320-11-000005 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,547 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.93 (range $39.81 to 40.02). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 16:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 307 | $34.17 | $10,490.19 |
DisclosureSEC source: 0000875320-10-000048 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,256 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan established under Rule 10b5-1. Read SEC document |
| July 14, 2010 Filed Jul 16, 2010 19:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 30,500 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0000875320-10-000044 · edgar.xml · derivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2020-07-13 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010. Read SEC document |
| June 28, 2010 Filed Jun 29, 2010 18:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 876 | $34.73 | $30,423.48 |
DisclosureSEC source: 0000875320-10-000035 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,563 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $34.73 (range $34.40 to $35.11). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 76,250 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000005 · edgar.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,250 Underlying: Common Stock · 76,250 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-10-000005 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,563 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| January 26, 2010 Filed Jan 27, 2010 22:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 583 | $39.48 | $23,016.84 |
DisclosureSEC source: 0000875320-10-000003 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,397 F1 · kind: Transaction made pursuant to Ms. Kelly's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.48 (range $39.14 to $39.63). F3 · price: Ms. Kelly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2009 Filed Nov 19, 2009 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 875 | $40.20 | $35,175.00 |
DisclosureSEC source: 0000875320-09-000097 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,980 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $40.20 (range $39.85 to 40.44). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 22, 2009 Filed Oct 26, 2009 20:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 60,000 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0000875320-09-000090 · edgar.xml · derivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2019-10-21 F1 · derivative.exercise_date: Stock option under 2006 Stock and Option Plan, vesting on 10/22/2014, subject to 20% acceleration upon receiving U.S. marketing approval for telaprevir; up to an additional 40% acceleration upon receiving U.S. approval for telaprevir if certain other performance goals are achieved; and 40% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of an additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| August 03, 2009 Filed Aug 4, 2009 19:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 319 | $36.09 | $11,512.71 |
DisclosureSEC source: 0000875320-09-000074 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,980 F1 · kind: Transaction made pursuant to Ms. Kelly's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.09 (range $36.09 to $36.11). F3 · price: Ms. Kelly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 16, 2009 Filed Jul 20, 2009 19:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $33.28 | $0.00 |
DisclosureSEC source: 0000875320-09-000064 · edgar.xml · derivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2019-07-15 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/16/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 45,750 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000010 · edgar.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-09-000010 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,299 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| July 24, 2008 Filed Jul 25, 2008 15:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 30,500 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0000875320-08-000059 · edgar.xml · derivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2018-07-23 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/24/2008. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-08-000010 · edgar.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 30,500 shares Expires 2018-02-06 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/07/2008, subject to shareholder approval. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,133 | $0.01 | $81.33 |
DisclosureSEC source: 0000875320-08-000010 · edgar.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,133 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/7/2012, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| July 12, 2007 Filed Jul 16, 2007 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000073 · edgar.xml · derivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2017-07-11 F1 · derivative.exercise_date: Right to buy under 2006 Stock and option Plan, vesting in 16 equal quarterly installments from 07/12/2007. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.